Manage stand orders
Select Option

Jiangsu Medomics Medical technology Co. Ltd

F3, Building D, No 3-1 Xinjinhu Road Jiangbei new Area, 210046 Nanjing
China
Telephone +86 25 58601060
Fax +86 25 58601060
info@medomics-dx.com

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

Media files

Contact

Julia Nee

Overseas Sales Director

Phone
008613512503340

Email
niling@medomics-dx.com

Jamie Gao

Overseas Sales

Phone
008615850618783

Email
jamie@medomics-dx.com

Tony Miao

Overseas Sales

Phone
008613865816778

Email
tonymiao@medomics-dx.com

Hazel Tang

E-commerce Specialist

Phone
008615996370312

Email
hazeltang@medomics-dx.com

Visit us

Unsettled / NN

16.11.2020

Topic

10:00 - 17:00

Online Showrooms, Company Videos & Live-Streams

17.11.2020

Topic

10:00 - 17:00

Online Showrooms, Company Videos & Live-Streams

18.11.2020

Topic

10:00 - 17:00

Online Showrooms, Company Videos & Live-Streams

19.11.2020

Topic

10:00 - 17:00

Online Showrooms, Company Videos & Live-Streams

Our products

Product category: Rapid tests in microbiology

MEDOMICS COVID-19 Solution - Antigen Rapid Test with more than 95% Sensitivity

Medomics Antigen Rapid test (LFIA) can test whether the patient is infected by COVID-19 virus in 15 to 20 minutes. Product is CE certificated and factory is BSI ISO13485 qualified.

Characateristics: 
Sensitivity: 96.64%
Specificity: 99.10% 
Reaction time: 15-20 min
Storage temperature:  2-30°C
Packing size: 20 tests/kit

More Less

Product category: Rapid tests in microbiology

MEDOMICS COVID-19 Solution- FDA Level Antibody Test

Medomics antibody rapid test for COVID-19 detection comes out very early in Feb 2020. After three times generation, the third generation antibody rapid test is even higher than FDA standard.

Characateristics:
Sensitivity: 100% 
Specificity: 99.09%
Reaction time: 15 min

More Less

Product category: Rapid tests in microbiology

MEDOMICS COVID-19 Solution - RNA Detection Kit

The Medomics RNA Detection Kit (Real-time PCR) provides rapid COVID-19 RNA Detection kit (Real-time PCR) provides rapid COVID-19 virus diagnostic by detecting high-specific ORF1ab and N genes from respiratory or serum samples.

More Less

Product category: Rapid tests in microbiology

MEDOMICS Flu A&B Antigen Test Kits (LFIA)

Medomics Flu A&B antigen Test Kits(LFIA) is used to qualitatively detect influenza virus type A and B antigens in human samples in vitro.

This product is used in the detection of samples from nasopharyngeal swab specimens of symptomatic patients by immunochromatography, which is suitable for the auxiliary diagnosis of type A and B antigens.

Influenza is a highly contagious ,actue, viral infection of the respiratory tract with symptoms such as headache, chills, dry cough, body aches and fever. It is a communicable disease that is easily transmitted through aerosolized droplets containing live virus from coughing and sneezing.

There are many types of influenza viruses, which are mainly divided into influenza A viruses, influenza B viruses and influenza C viruses. Influenza A viruses have extremely strong variability, followed by influenza B viruses, and influenza C viruses are very stable, so influenza A viruses are more prevalent and serious.

Characteristics:
Sensitivity:>95%
Specificity: 100%
Reaction Time: 10mins
Sample: nasopharyngeal swab specimens
Storage temperature: 4-30℃

More Less

Product category: Rapid tests in microbiology

MEDOMICS Flu A&B and SARS-CoV-2 Antigen Test Kits (LFIA)

Medomics Flu A&B and SARS-CoV-2 antigen Test Kit (LFIA) is used to qualitatively detect influenza virus type A, influenza virus typeB and SARS-CoV-2 antigens in human samples in vitro.

Coronavirus (CoV) belongs to the order Nidovirales under the Coronaviridae family with 4 genera: α, β, γ and δ. The α and β genera are only pathogenic to mammals, while γ and δ genera mainly causes bird infections.

7 kinds of human coronaviruses (HCoV) that cause human respiratory diseases have been identified so far, including: HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1, SARS-CoV, MERS-CoV and SARS-CoV-2. SARS-CoV-2 is one of the most contagious viral pathogens that causes human respiratory tract infections (RTI). Currently, the patients infected by novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days. The clinical manifestations include fever, fatigue, cough and other symptoms, accompanied by dyspnea, which can rapidly develop into life-threatening severe pneumonia, respiratory failure, acute respiratory vesicle syndrome, septic shock, multiple organ failure, and severe metabolic acid-base imbalance.

Influenza is a highly contagious ,actue, viral infection of the respiratory tract with symptoms such as headache, chills, dry cough, body aches and fever. Influenza and Coronavirus are communicable diseases that are easily transmitted through aerosolized droplets containing live virus from coughing and sneezing.

Since Flu A&B and SARS-CoV-2 have similar symptoms and routes of infection, the kit has important clinical significance in identifying them.

Characteristics:
Sensitivity:>95%
Specificity: 100%
Reaction Time:10mins
Sample:nasopharyngeal swab specimens
Storage temperature:4-30℃

More Less

Product category: Rapid tests in microbiology

MEDOMICS SARS-CoV-2 Neutralizing antibody Test Kit (ELISA)

The Medomics SARS-CoV-2 Neutralizing antibody Test Kit (ELISA) is suitable for in vitro qualitative detection of SARS-CoV-2 neutralizing antibodies in human serum samples.

SARS-CoV-2 Neutralizing antibody is an important marker for assessing the effectiveness of the new coronavirus vaccines.This reagent is suitable for neutralizing antibody detection in the samples from individuals with vaccine injection people and recovered people.

SARS-CoV-2 Neutralizing antibody Test Kit (ELISA) is of great significance for the development of new coronavirus vaccines, evaluation of effectiveness, and evaluation of neutralizing antibody levels in the population.

Characteristics:
Sensitivity:>98%
Specificity:>100%
Reaction Time: 70min
Sample: serum
Storage temperature: 2-8℃

More Less

Product category: Rapid tests in microbiology

MEDOMICS Aurora - Dual Fluorescent Staining Kit

Medomics Clinical morphological standard for vaginal infection

More Less

Product category: Rapid tests in microbiology

MEDOMICS Minomics Autostainer

Medomics Clinical morphological standard for vaginal infection

Characateristics:
Speed: 30s/slide
Dyeing method: Drop dyeing
Capacity: 1 slide
Dyeing principle: Specific fluorescent staining

More Less

Company news

Date

Topic

Download

Oct 6, 2020

Opening A New Mode of Agency - the Exchange Meeting between GCHW and Medomics Medical Successfully Held

Golden autumn in October, under the beautiful Qinhuai River, under the antique Dinghuai Gate, the annual meeting of Obstetrics and Gynecology of Jiangsu Medical Association, the exchange meeting of the new project of Gynecological Reagents by Guokong Wende & Jiangsu Medomics Convened.

On October 31, the annual meeting of Obstetrics and Gynecology of Jiangsu Medical Association was grandly opened in Kangxin Building of Jiangsu Maternal and Child Health Hospital. The meeting invited lecturers from inside and outside the province to present a wealth of spiritual food for participating doctors.

On the occasion of the annual meeting of obstetrics and gynecology, we invited the business cooperation elites in the field of obstetrics and gynecology in the province to gather at Jinling Jingyuan Hotel to jointly participate in the project exchange meeting of Guokong Wende & Jiangsu Medomics.

Next, let us feel the warm atmosphere of the conference together!

1, Leader's speech | Xu Yan, deputy general manager of Guokong Wende
The meeting kicked off with a speech by Mr. Xu, Deputy General Manager of Wende State Control. Mr. Xu insists on leading the team to make a comprehensive professional transformation to adapt to the changes in the unemployed medical market and make the company more competitive in the market. At the same time, Mr. Xu is full of hope for the future development of gynecological reagents, hoping to create a new model of a strong alliance between industry and commerce, with products as the carrier, and a network of core experts to establish a new model of marketing platform.

2. Introduction of Jiangsu Medomics | Yang Yongjun, Deputy General Manager of Medomics
This conference is very honored to be able to invite Professor Zhou Huaijun to teach on-site. Professor Zhou Huaijun is the appointed chairman of the Obstetrics and Gynecology Branch of Jiangsu Medical Association and the director of the gynecology department of Nanjing Gulou Hospital. He has rich clinical experience and experience in diagnosis and treatment. This time, Professor Zhou introduced the epidemiology and detection methods of gynecological inflammation to all partners, and emphasized that morphology is the gold standard for vaginal microbiological examination. Finally, it is concluded that the development of industry has promoted the development of medicine, and the development of medical diagnosis accounts for a very important proportion. Only accurate diagnosis can provide correct treatment.

4. Introduction to the progress of the gynecology project
General Manager Fei Di , Director of Gynecology and Gynecology Program of National Control Wende introduced the progress of the project to the participants. From the launch of the project in 2019, the gynecology project team has docked with a number of first-line gynecology experts in the province, and has held high-quality satellite conferences in and outside the province many times. The project has been recognized and supported by authoritative gynecology experts. At present, many large tertiary hospitals in the province have made substantial progress. I believe that in the next year, we can reach cooperation with more partners to provide more accurate diagnosis for more patients.

5. Project demonstration and project Q&A|Pan Liang, Sales Director of Jiangsu Medomics
In the last part of the meeting, we used the meeting connection method to operate on-site and present the images on the big screen, making the whole process more intuitive. In this session, Mark Pan Liang, Sales Director of Medomics, gave a detailed introduction to the entire process of reagent operation. The whole process from smearing, staining to reporting is no more than 2 minutes. At the same time, the pathogenic microorganisms are clearly visible after staining, which greatly improves the work efficiency of medical staff. At the end of the demonstration, everyone went to the reagent project instrument to get a close understanding of each operation link. At the same time, the participants had a lively discussion on market and clinical related issues.

Many partners reached cooperation intentions with Guokong Wende on the spot, and invited academic staff from the marketing department to the local for product training and expert visits.

6. Ending|In-depth negotiation and docking
Every intentional partner is still communicating with the counterparty about their cooperation intentions. The colleagues in the business development department are full of passionate smiles. This investment promotion conference is coming to an end. The meeting achieved the expected results. The participants had a deeper understanding of the national control Wende, Jiangsu Medomics, Gynecology Project and the teams of the two companies, and laid a solid foundation for future cooperation.

Although the meeting is over, our docking work has only begun. Next, we will enter an active docking stage, turn intentional cooperation into active cooperation, incorporate more and more partners into our project, and provide more accurate diagnosis for more patients. Let us look forward to it together!

More Less

Aug 31, 2020

Medomics Medical's Four COVID-19 Testing Products Received CE Mark

On August 26, 2020,  Medomics Medical receieved CE mark for the following four  COVID-19 testing products:

SARS-CoV-2 Antigen Test kit (ELISA)
            Medomics (NL-CA002-2020-53183)
SARS-CoV-2 Antigen Test Kit (LFIA)
             Medomics (NL-CA002-2020-53182)
SARS-CoV-2 Neutralizing Antibody Test Kit (ELISA)
              Medomics (NL-CA002-2020-53180)
SARS-CoV-2 Neutralizing Antibody Test Kit (LFIA)
              Medomics (NL-CA002-2020-53181)

As of press time, Medomics Medical’s  COVID-19 series of products have passed ISO 13485: 2016 Medical Device Quality Management System, and a total of five COVID-19 testing products of Medomics Medical have obtained CE certificate ranging from the earliest antigen detection to early and mid-term antibody testing after infection, as well as the neutralizing antibody (protective antibody) test produced by patients after vaccination or recovery, which covers the entire cycle of  detection of COVID-19.

More Less

About us

Company details

Jiangsu Medomics Medical Technology Co., Ltd., is located at Biotech and Pharmaceutical Valley of the National Jiangbei New Area, Nanjing, Jiangsu Province. It is an international high-tech enterprise driven by innovation in the area of medical devices R&D, production and sales. Medomics focuses on diagnosis of microorganisms, tumors and some rare diseases, mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and automatic instruments.  

Medomics owns two R&D centers in China and the US, independent intellectual property rights of fluorescent staining technology, protein labeling technology, time-resolved immunofluorescence detection technology, image processing and analysis technology and other innovative technology platforms, as well as a total of more than 10,000 square meters of GMP purification production workshop that meets the product standards of FDA, CE and CFDA. Until now, Medomics has more than 100 employees across the world and R&D personnel accounts for over 50%. Medomics also has a multidisciplinary expert team with abundant experience in the industry, including senior experts in immunology, microbiology, applied physics, polymer materials, medical imaging, optical systems, etc. The members of the technical team are led by doctors from many famous institutions, such as Osaka University, North Carolina University, University of Nebraska Lincoln, Zhejiang University, Sichuan University and other institutions.

At the very beginning of COVID-19 on early 2020, Medomics developed IgM/IgG antibody detecting kit with the team of Zhong Nanshang. And Medomics published the first research paper on international journal together with State Key Laboratory of Respiratory Disease (National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health). The detecting kit was validated by CDC, Harvard Medical School and Columbia University Irving Medical Center etc. Until May 2020, the kit has been exported to dozens of countries and areas, making great help against SARS-Cov-2.

At present, Medomics’s series product of SARS-Cov-2 detection have been developed according to ISO 13485 Quality system and European CE Certification.

More Less

Company data

Sales volume

10-49 Mio US $

Number of employees

100-499

Area of business
  • Electromedical equipment / Medical Technology
  • Diagnostics

Company information as a PDF file